Therapeutic approaches to hepatocellular carcinoma

Drugs of the Future

Volumn 33, Issue 1, 2008, Pages 75-83

  Borgia, Beatrice ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALCOHOL; ALEMTUZUMAB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IBRITUMOMAB TIUXETAN; INTERFERON; IODINATED POPPYSEED OIL; IRINOTECAN; METUXIMAB; MITOMYCIN C; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AF 20; MONOCLONAL ANTIBODY F 19; NOLATREXED; PACLITAXEL; RITUXIMAB; SORAFENIB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MONOTHERAPY; PROGNOSIS; RADIOFREQUENCY ABLATION; RADIOIMMUNOTHERAPY; REVIEW; TUMOR VOLUME;

EID: 40949116787     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.01.1143489     Document Type: Review

References (86)

1. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2): 74-108.
2. Deuffic, S., Poynard, T., Buffat, L., Valleron, A.J. Trends in primary liver cancer. Lancet 1998, 351(9097): 214-5.
3. El-Serag, H.B., Mason, A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340(10): 745-50.
4. Tanaka, Y., Hanada, K., Mizokami, M., Yeo, A.E., Shih, J.W., Gojobori, T., Alter, H. J. Inaugural article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002, 99(24): 15584-9.
5. Capocaccia, R., Sant, M., Berrino, F., Simonetti, A., Santi, V., Trevisani, F. Hepatocellular carcinoma: Trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007, 102(8): 1661-70.
6. Bosch, F.X., Ribes, J., Cleries, R., Diaz, M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005, 9(2): 191-211.
7. Bruix, J., Boix, L., Sala, M., Llovet, J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5(3): 215-9.
8. Barazani, Y., Hiatt, J.R., Tong, M.J., Busuttil, R.W. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007, 31(6): 1245-50.
9. Bruix, J., Hessheimer, A.J., Forner, A., Boix, L., Vilana, R., Llovet, J.M. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006, 25(27): 3848-56.
10. Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60(8): 646-9.
11. Okuda, K., Ohtsuki, T., Obata, H. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56(4): 918-28.
12. Llovet, J.M., Bru, C., Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999, 19(3): 329-38.
13. Farinati, F., Rinaldi, M., Gianni, S., Naccarato, R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000, 89(11): 2266-73.
14. Leung, T.W., Tang, A.M., Zee, B. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 2002, 94(6): 1760-9.
15. Ikai, I., Takayasu, K., Omata, M. et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006, 41(9): 884-92.
16. Kudo, M., Chung, H., Osaki, Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003, 38(3): 207-15.
17. Poon, R.T., Fan, S.T. Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome. Liver Transpl 2004, 10(2, Suppl. 1): S39-45.
18. Bruix, J., Castells, A., Bosch, J. et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 1996, 111(4): 1018-22.
19. Llovet, J.M., Schwartz, M., Mazzaferro, V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2): 181-200.
20. Cillo, U., Vitale, A., Brolese, A. et al. Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. J Surg Oncol 2007, 95(3): 213-20.
21. Imamura, H., Matsuyama, Y., Tanaka, E. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38(2): 200-7.
22. Takayama, T., Sekine, T., Makuuchi, M. et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000, 356(9232): 802-7.
23. Lau, W.Y., Leung, T.W., Ho, S.K. et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet 1999, 353(9155): 797-801.
24. Ono, T., Yamanoi, A., Nazmy El Assal, O., Kohno, H., Nagasue, N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: Metaanalysis of three randomized controlled trials. Cancer 2001, 91(12): 2378-85.
25. Muto, Y., Moriwaki, H., Ninomiya, M. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334(24): 1561-7.
26. Shiratori, Y., Shiina, S., Teratani, T. et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003, 138(4): 299-306.
27. Iwatsuki, S., Starzl, T.E., Sheahan, D.G. et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991, 214(3): 221-8; discussion 228-9.
28. Ringe, B., Pichlmayr, R., Wittekind, C., Tusch, G. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients. World J Surg 1991, 15(2): 270-85.
29. Mazzaferro, V., Regalia, E., Doci, R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11): 693-9.
30. Figueras, J., Jaurrieta, E., Valls, C. et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study. Hepatology 1997, 25(6): 1485-9.
31. Yoo, H.Y., Patt, C.H., Geschwind, J.F., Thuluvath, P.J. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and2001: 5-Year survival has improved significantly with time. J Clin Oncol 2003, 21(23): 4329-35.
32. Yao, F.Y., Bass, N.M., Nikolai, B. et al. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002, 8(10): 873-83.
33. Poon, R.T. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: Transplantation or resection? Ann Surg Oncol 2007, 14(2): 541-7.
34. Fisher, R.A., Kulik, L.M., Freise, C.E. et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007, 7(6): 1601-8.
35. Todo, S., Furukawa, H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan. Ann Surg 2004, 240(3): 451-9; discussion 459-61.
36. Brown, R.S. Jr., Russo, M.W., Lai, M. et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003, 348(9): 818-25.
37. Stigliano, R., Marelli, L., Yu, D., Davies, N., Patch, D., Burroughs, A.K. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007, 33(5): 437-47.
38. Lencioni, R., Pinto, F., Armillotta, N. et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: A European experience. Eur Radiol 1997, 7(4): 514-9.
39. Ebara, M., Okabe, S., Kita, K. et al. Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation. J Hepatol 2005, 43(3): 458-64.
40. Okusaka, T., Okada, S., Ueno, H. et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002, 95(9): 1931-7.
41. Ohnishi, K., Ohyama, N., Ito, S., Fujiwara, K. Small hepatocellular carcinoma: Treatment with US-guided intratumoral injection of acetic acid. Radiology 1994, 193(3): 747-52.
42. Ohnishi, K., Yoshioka, H., Ito, S., Fujiwara, K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998, 27(1): 67-72.
43. Liang, H.L., Yang, C.F., Pan, H.B. et al. Small hepatocellular carcinoma: Safety and efficacy of single high-dose percutaneous acetic acid injection for treatment. Radiology 2000, 214(3): 769-74.
44. Goldberg, S.N., Gazelle, G.S., Mueller, P.R. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000, 174(2): 323-31.
45. Shibata, T., Shibata, T., Maetani, Y., Isoda, H., Hiraoka, M. Radiofrequency ablation for small hepatocellular carcinoma: Prospective comparison of internally cooled electrode and expandable electrode. Radiology 2006, 238(1): 346-53.
46. Lencioni, R., Delia Pina, C., Bartolozzi, C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging 2005, 30(4): 401-8.
47. Lin, S.M., Lin, C.J., Lin, C.C., Hsu, C.W., Chen, Y.C. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54(8): 1151-6.
48. Angonese, C., Baldan, A., Cillo, U. et al. Complications of radiofrequency thermal ablation in hepatocellular carcinoma: What about "explosive" spread? Gut 2006, 55(3): 435-6.
49. Seki, T., Wakabayashi, M., Nakagawa, T. et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994, 74(3): 817-25.
50. Dong, B., Liang, P., Yu, X., Su, L., Yu, D., Cheng, Z., Zhang, J. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: Results in 234 patients. AJR Am J Roentgenol 2003, 180(6): 1547-55.
51. Lu, M.D., Xu, H.X., Xie, X.Y. et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: A retrospective comparative study. J Gastroenterol 2005, 40(11): 1054-60.
52. Ohmoto, K., Yoshioka, N., Tomiyama, Y. et al. Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: A retrospective comparative study. Hepatogastroenterology 2007, 54(76): 985-9.
53. Gage, A.A., Baust, J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998, 37(3): 171-86.
54. Helling, T.S. Realistic expectations for cryoablation of liver tumors. J Hepatobiliary Pancreat Surg 2000, 7(5): 510-5.
55. Bageacu, S., Kaczmarek, D., Lacroix, M., Dubois, J., Forest, J., Porcheron, J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol 2007, 33(5): 590-6.
56. Kennedy, J.E., Ter Haar, G.R., Cranston, D. High intensity focused ultrasound: Surgery of the future? Br J Radiol 2003, 76(909): 590-9.
57. Wu, F., Wang, Z.B., Chen, W.Z. et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann Surg Oncol 2004, 11(12): 1061-9.
58. Li, J.J., Xu, G.L., Gu, M.F., Luo, G.Y., Rong, Z., Wu, P.H., Xia, J.C Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors. World J Gastroenterol 2007, 13(19): 2747-51.
59. Wu, F., Wang, Z.B., Chen, W.Z. et al. Advanced hepatocellular carcinoma: Treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization. Radiology 2005, 235(2): 659-67.
60. Llovet, J.M., Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37(2): 429-42.
61. Bhattacharya, S., Novell, J.R., Winslet, M.C., Hobbs, K.E. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994, 81(11): 1563-71.
62. Varela, M., Real, M.I., Burrel, M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46(3): 474-81.
63. Marelli, L., Stigliano, R., Triantos, C. et al. Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30(1): 6-25.
64. Llovet, J.M., Real, M.I., Montana, X. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002, 359(9319): 1734-9.
65. Gish, R.G., Porta, C., Lazar, L. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007, 25(21): 3069-75.
66. Yeo, W., Mok, T.S., Zee, B. et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97(20): 1532-8.
67. Dobbs, N.A., Twelves, C.J., Rizzi, P., Warwick, J.D., Metivier, E.M., Williams, R., Johnson, P.J. Epirubicin in hepatocellular carcinoma: Pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994, 34(5): 405-10.
68. Zhu, A.X. Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist 2006, 11(7): 790-800.
69. Philip, P.A., Mahoney, M.R., Allmer, C. et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23(27): 6657-63.
70. Abou-Alfa, G.K., Schwartz, L., Ricci, S. et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(26): 4293-300.
71. Walsh, G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006, 24(7): 769-76.
72. Carter, P.J. Potent antibody therapeutics by design. Nat Rev Immunol 2006, 6(5): 343-57.
73. Adams, G.P., Weiner, L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23(9): 1147-57.
74. Welt, S., Divgi, C.R., Scott, A.M. et al. Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-suriace protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994, 12(6): 1193-203.
75. Rybak, J.-N., Roesli, C., Kaspar, M., Villa, A., Neri, D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 2007, 67(22): in press.
76. Mohr, L., Yeung, A., Aloman, C., Wittrup, D., Wands, J.R. Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology 2004, 127(5, Suppl. 1): S225-31.
77. Chen, Z.N., Mi, L., Xu, J. et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006, 65(2): 435-44.
78. Zeng, Z.C., Tang, Z.Y., Liu, K.D., Lu, J.Z., Xie, H., Yao, Z. Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 1998, 124(5): 275-80.
79. Zhu, A.X., Blaszkowsky, L.S., Ryan, D.P. et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(12): 1898-903.
80. Zhu, A.X., Stuart, K., Blaszkowsky, L.S. et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110(3): 581-9.
81. Carnemolla, B., Borsi, L., Balza, E. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99(5): 1659-65.
82. Ebbinghaus, C., Ronca, R., Kaspar, M. et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005, 116(2): 304-13.
83. Halin, C., Gafner, V., Villani, M.E. et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003, 63(12): 3202-10.
84. Menrad, A., Menssen, H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005, 9(3): 491-500.
85. Neri, D., Bicknell, R. Tumour vascular targeting. Nat Rev Cancer 2005, 5(6): 436-46.
86. Rybak, J.N., Trachsel, E., Scheuermann, J., Neri, D. Ligandased vascular targeting of disease. ChemMedChem 2007, 2(1 ): 22-40.